|
Antioxidant |
Free radicals |
3
|
[30] |
Synthetic |
|
Antioxidant |
Free radicals |
9
|
[35] |
Synthetic |
|
Antioxidant |
Free radicals |
10d
|
[36] |
Synthetic |
|
Antioxidant |
Free radicals |
15
|
[38] |
Synthetic |
|
Antiprolifera-tive |
DNA, chromatin |
18
|
[45] |
Natural |
|
Antiprolifera-tive |
Topoisomerase 1 |
20
|
[47] |
Synthetic |
|
Antiprolifera-tive |
Tumor-suppressor protein p53 |
21
|
[49] |
Synthetic |
|
Anticancer |
|
22a-l
|
[50] |
Synthetic |
|
Anticancer |
STAT3 |
23
|
[55] |
Synthetic |
|
Anticancer |
Carbonic Anhydrase IX and XII |
24
|
[70] |
Natural |
|
Anticancer |
Carbonic Anhydrase IX and XII |
26–37
|
[71] |
Synthetic |
|
Antibacterial/antifungal |
S. aureus, E. coli, P. aeruginosa, A. niger, A. flavus, C. albicans
|
38,39
|
[79] |
Synthetic |
|
Antibacterial |
S. aureusus, E.faecalis, E. coli
|
40,41a–e
|
[80] |
Synthetic |
|
Antibacterial |
S. aureus DNA gyrase |
42–49
|
[82] |
Synthetic |
|
Antibacterial |
S. aureus
|
50,51
|
[83] |
Synthetic |
|
Modulator of antibiotics |
n.g. |
isopimpinellin imperatorin |
[85] |
Natural |
|
Antibacterial |
S. aureus, S. epidermidis, P. aeruginosa, E. cloacae, K. Pneumoniae, E. coli
|
6′,7′-dihydroxybergamottin, peucedanin, officinali isobutyrate |
[86] |
Natural |
|
Antibacterial |
S. aureus, L. monocytogenes, E. coli, Salmonella—inhibitors of Topo II and Topo IV |
52–54
|
[87] |
Synthetic |
|
Antifungal |
C. albicans -P450 cytochrome lanosterol 14α-demethylase |
55–59
|
[94] |
Synthetic |
|
Antifungal |
C. albicans—inhibition ergosterol biosynthesis by binding lanosterol 14a-demethylase |
60,61
|
[95] |
Synthetic |
|
Antifungal |
Several Candida strains—mode of action involving CYP51 and additional unidentified mechanism |
62
|
[96] |
Synthetic |
|
Antifungal |
C. albicans
|
marmesin senesioate, suberosin, crenulatin |
[97] |
Natural |
|
Antifungal |
C. albicans—antibiofilm action
|
coumarin |
[100] |
Natural |
|
Antifungal |
F. oxysporum, A. flavus, A. niger
|
63–68
|
[102] |
Synthetic |
|
Antiviral |
Anti-HIV reverse transcriptase |
69–71
|
[113] |
Natural |
|
Antiviral |
HIV reverse transcriptase |
72–74
|
[116] |
Natural |
|
Antiviral |
HIV1-IN |
75–78
|
[117] |
Synthetic |
|
Antiviral |
H1N1 virus |
79–82
|
[125] |
Synthetic |
|
Antiviral |
Influenza A virus |
83
|
[128] |
Synthetic |
|
Antiviral |
Influenza A/PR8/H1N1 viruses—probably could affect intracellular redox-sensitive pathways |
84–89
|
[129] |
Synthetic |
|
Antiviral |
Hepatitis C virus |
90–92
|
[130] |
Synthetic |
|
Antiviral |
Hepatitis B virus |
esculetin |
[131] |
Natural |
|
Antiinflamma-tory |
COX2 |
93–100
|
[143] |
Synthetic |
|
Antiinflamma-tory |
5-LOX |
101,102
|
[146] |
Synthetic |
|
Antiinflamma-tory |
NO production |
103
|
[147] |
Natural |
|
Antiinflamma-tory |
NF-kB and p38/MAPK signaling pathways |
osthole |
[150] |
Natural |
|
Antiinflamma-tory |
NF-kB signaling pathways |
104
|
[151] |
Synthetic |
|
Anti-Alzhemer’s disease |
AChE, BuChE, BACE1 |
105
|
[162] |
Synthetic |
|
Anti-Alzhemer’s disease |
AChE, BuChE, BACE1, metal chelation |
107
|
[163] |
Synthetic |
|
Anti-Alzhemer’s disease |
AChE, BuChE, BACE1 |
108
|
[163] |
Synthetic |
|
Anti-Alzhemer’s disease |
AChE, BuChE |
111a
|
[166] |
Synthetic |
|
Anti-Alzhemer’s disease |
AChE, BuChE, MAO-B |
117
|
[167] |
Synthetic |
|
Anti-Alzhemer’s disease |
AChE, BuChE, MAO-B, β-amyloid aggregation |
136
|
[169] |
Synthetic |
|
Anticonvulsant |
GABAergic system |
148
|
[180] |
Synthetic |
|
Anticonvulsant |
BDZ receptor |
152d
|
[183] |
Synthetic |
|
Anticoagulant |
VKOR inhibitor |
Tecarfarin(ATI-5923) |
[195,196,197,198] |
Synthetic |
|
Anticoagulant |
n.g. |
154,155
|
[199] |
Synthetic |
|
Anticoagulant |
murine VKORC1 inhibitor |
156
|
[200] |
Synthetic |
|
Anticoagulant |
n.g. |
157
|
[203] |
Natural |
|
Antidiabetic |
α-glucosidases |
158d,e
|
[207] |
Synthetic |
|
Antidiabetic |
α-glucosidases |
159d,e
|
[207] |
Synthetic |
|
Antidiabetic |
α-glucosidases |
165
|
[214] |
Synthetic |
|
Antidiabetic |
α-glucosidases |
168c
|
[215] |
Synthetic |
|
Antidiabetic |
Insulin release |
169–171
|
[217] |
Synthetic |
|
Photocleavable protecting groups |
- |
172–174
|
[231,232] |
Synthetic |
|
Photocleavable protecting group |
- |
175
|
[224] |
Synthetic |
|
Photocleavable protecting groups |
- |
176–178
|
[233] |
Synthetic |
|
Ionic probe |
GHS (in the presence of Cu2+) and ClO−
|
179
|
[236,237] |
Syntehtic |
|
Ionic probe |
ClO−
|
180
|
[238] |
Synthetic |
|
Ionic probe |
ClO−, Cu2+
|
181
|
[239] |
Synthetic |
|
Ionic probe |
ClO−
|
182–184
|
[240] |
Synthetic |
|
Ionic probe |
Cu2+
|
185
|
[241] |
Synthetic |
|
Ionic probe |
Cu2+
|
186
|
[242] |
Synthetic |
|
Ionic probe |
Cu2+
|
187
|
[243] |
Synthetic |
|
Ionic probe |
Cu2+, Al3+, Arg, Lys, Cys, Hcy, GSH |
188
|
[244] |
Synthetic |
|
Ionic probe |
Pd2+
|
189
|
[245] |
Synthetic |
|
Ionic probe |
Hg2+
|
190,191
|
[246] |
Synthetic |
|
Ionic probe |
Fe3+
|
192
|
[247] |
Synthetic |
|
Ionic probe |
F−
|
193
|
[248] |
Synthetic |
|
Ionic probe |
F−, Ca2+
|
194
|
[249] |
Synthetic |
|
Ionic probe |
F−, CN−
|
195
|
[250] |
Synthetic |
|
Probe |
HSO3−, SO32− ion |
196
|
[251] |
Synthetic |
|
Probe |
HSO4− and SO42−
|
CG, CA |
[256] |
Synthetic |
|
Antibacterial |
R. Solanacearum, genes fliA, flhC, biofilm formation |
umbelliferone, esculetin, daphnetin, xanthotol |
[261] |
Natural |
|
Fungicide |
Colletotrichum sp. |
197–202
|
[265] |
Natural |
|
Fungicide |
Botrytis cinerea, Alternaria solani, Gibberella zeae, Rhizoctorzia solani, Cucumber anthrax and Alternaria
|
203,204
|
[268] |
Synthetic |
|
Fungicide: |
Alternaria solani sorauer, Fusarium oxysporum f.sp. vasinfectum and Fusarium moniliforme
|
205a–d
|
[273] |
Synthetic |
|
Anticancer |
MCF-7 human breast cancer cells |
207–213
|
[276] |
Synthetic |
|
Anticancer |
Human lung adenocarcinoma (A549/DDP) and HeLa cells |
214–224
|
[281] |
Synthetic |
|
Catalyst |
|
225
|
[282] |
Synthetic |